date:Sep 17, 2013
nt on the lease renewal of the companys grow-out facility in Panama.
We remain confident of receiving approval for our new animal drug application for AquAdvantage Salmon. The basis of our confidence is that, since the public meetings in September 2010, there hasn't been a single new substantive scientific or legal argument presented to the FDA against our application, said Rob Stotish, CEO. This makes us hopeful that the strength of law, due process and science-based regulation will prevail, a